MIG Co., Ltd.
With the appointment of Takahiko Tokuda, a leading expert in dementia blood biomarker clinical research, as a medical advisor, MIG Co., Ltd. will strengthen the medical position of VR measurement and strengthen its ability to expand to medical institutions.
MIG Co., Ltd. (President: Hidetaka Kai, Head Office: Shibuya-ku, Tokyo, hereinafter referred to as MIG) is pleased to announce that Mr. Takahiko Tokuda has been appointed as our medical advisor.
The aim of inviting Mr. Takahiko Tokuda this time:
MIG provides ultra-early diagnosis of Alzheimer’s type dementia and support services for prevention activities from an extremely early stage. We are promoting our business.
Meanwhile, an amyloid-β inhibitor (Eisai Co., Ltd.’s “Rekenbi (R) Intravenous Injection” (generic name: lecanemab)) has been approved by the FDA, and has also received regulatory approval in Japan, and clinical administration has begun as a treatment for Alzheimer’s disease. Masu. How to screen patients for whom treatment is effective from among a large number of potential patients has become a huge social issue.
By measuring spatial navigation brain function using VR goggles developed by MIG, we are developing an approach to determine Alzheimer’s disease based on the decrease in accuracy caused by cell destruction in the entorhinal cortex in the very early stages of Alzheimer’s disease. It has been found that there is a very high correlation with multiple blood biomarkers that can be used to determine early stages.
Mr. Takahiko Tokuda is a leading expert in the research field of dementia blood biomarkers, and serves as the medical director of the Brain Functional Imaging Research Department, Institute for Quantum Medical Science, Division of Quantum Life and Medicine, National Institutes for Quantum and Radiological Science and Technology. He founded T&T Brothers, a venture company originating from a research and development corporation that provides early detection of dementia using blood biomarkers and accurate diagnosis based on brain pathology. We aim to implement diagnostic technology in society. We plan to expand collaboration with the company’s blood biomarker testing in the future as a detailed test for subjects with large error distances in VR measurement results.
[Mr. Tokuda Profile]
1984 Graduated from Shinshu University School of Medicine
1992: Obtained Doctor of Medicine from Shinshu University
Affiliated societies: Japanese Society of Neurology (neurologist specialist), Japanese Society of Internal Medicine (certified internal medicine physician, certified internal medicine specialist), Japanese Dementia Society (certified specialist, delegate), Japanese Normal Pressure Hydrocephalus Society (director),
ISTAART (Alzheimer’s Association International Society to Advance Alzheimer’s Research
1984: Worked at Shinshu University Hospital, Assistant at Shinshu University Hospital
1993 Visiting Researcher, Tokyo Metropolitan Institute of Psychiatry (Protein chemical research on Alzheimer’s disease) (until March 1995) 1995 Postdoctoral Fellow, Department of Pathology, New York University School of Medicine (Professor B.Frangione)
(For protein chemical research on Alzheimer’s disease) (until March 1999) 1999: Assistant, full-time lecturer, Shinshu University Hospital, full-time assistant professor, Aging Adaptation Research Center, Shinshu University School of Medicine,
Associate Professor, Department of Molecular Cytology, Department of Neuroplasticity, Department of Aging and Adaptation Medical Sciences, Shinshu University Graduate School of Medicine
2005: Lecturer, Department of Neurology, Kyoto Prefectural University of Medicine, Graduate School of Medicine, Kyoto Prefectural University of Medicine, Graduate School of Medicine
Molecular brain pathology analysis (concurrent with neurology) (Associate professor)
Kyoto Prefectural University of Medicine, Molecular Brain Pathology Analysis (Professor) (Concurrently in Neurology)
2020 National Institutes for Quantum Science and Technology, Division of Quantum Life Science and Medicine, Institute for Quantum Medical Science, Department of Brain Functional Imaging, Medical Director [Image 1
Mr. Takahiko Tokuda appointed
MIG Medical Advisor Takahiko Tokuda
“Tokuda has been working on the development of blood and cerebrospinal fluid biomarkers (BM) for dementia and neurodegenerative diseases for over 20 years. The leading PET diagnostic method development research for brain diseases and Tokuda’s body fluid BM research are an ideal combination that can accelerate the development of each other’s research, and Tokuda’s blood BM has confirmed brain pathology using PET images. It is a highly accurate BM that has been verified using patient blood.There are very few groups in the world that
systematically conduct research on both image diagnosis BM and body fluid BM, so QST is a world leader in these studies. In addition, TTB, founded by Tokuda, is a QST-originated venture to socially implement the BM technology created by QST, which is leading the world. Tokuda I look forward to working with the MIG team as they continue to grow.” MIG President and CEO Hidetaka Kai
“We have been able to welcome Dr. Takahiko Tokuda as an advisor, and we are finally able to lead to ultra-early detection, detailed examinations, definitive diagnosis, and treatment with Alzheimer’s disease drugs at medical institutions, which is necessary to accelerate social implementation. We believe that this will be an important step in positioning VR measurement in the process of progress.In order to popularize ultra-early screening for a wide range of potential patients, which MIG aims to do, the combination with blood biomarker testing will be an important step for medical institutions to use. I think this is very important from the perspective of escalation.Dr. Tokuda is a leading expert in the field of dementia blood biomarker testing research, which has confirmed a very high correlation with VR measurement results, and he himself However, he founded T&T Brothers, a company that provides early detection of dementia using blood biomarkers developed by the National Institutes of Quantum and Radiological Science and Technology and accurate diagnosis based on brain pathology. However, I am very pleased to have a dementia specialist appointed as an advisor who will contribute to the future development of MIG.”
[Institute for Quantum Medical Science, Division of Quantum Life and Medicine, National Institutes for Quantum Science and Technology] https://www.qst.go.jp/site/qms/1869.html
The Institute for Quantum Medical Science utilizes various quantum science technologies and collaborates with researchers and engineers in medicine, pharmacy, biology, chemistry, physical engineering, etc. to conduct medical science research from basics to clinical practice. We are proceeding.
The Institute for Quantum Medical Science uses quantum sensor technology and nuclear medicine diagnosis to elucidate the mechanism of Alzheimer’s disease and other psychiatric and neurological diseases, and develop diagnostic and therapeutic methods. We are conducting research and development aimed at miniaturizing heavy ion radiotherapy equipment, improving its performance, and improving the effectiveness of heavy ion radiotherapy. Furthermore, we are promoting research and development of innovative radiation cancer diagnostic treatment called targeted isotope therapy using alpha-emitting nuclei. In these research areas, the Institute for Quantum Medical Science has high research and development capabilities that can compete not only with Japan but also with the world.
[T&T Brothers Co., Ltd.] http://www.ttb.co.jp/
It is a company issued by the National Institute for Quantum and Radiological Science and Technology that conducts liquid biopsy, which develops blood-based testing technology with the aim of early detection of dementia and accurate diagnosis based on brain pathology. We aim to socially implement molecular diagnostic technology. By developing a method for testing and measuring dementia using blood biomarkers, we aim to create a society where early detection and treatment can be achieved through inexpensive, simple, and less risky testing.
In 2017, we developed the world’s first method to measure the protein that causes dementia (phosphorylated tau) in blood, and in April 2023, we developed a method to measure abnormal tau protein accumulation in the brain (a protein that directly causes the death of brain nerve cells). We have developed the world’s first blood biomarker that accurately reflects blood, and have applied for patents for both. The founding members conduct research at the National Institute for Quantum and Radiological Science and Technology, and in addition to phosphorylated tau, they have ultra-sensitive measurement technology for over 10 blood biomarkers.
We are working on research every day to improve the precision and accuracy of testing for early detection of dementia. Brain100 studio (Video 1) This is a Takashima-style Alzheimer’s disease ultra-early screening test program using VR goggles provided by MIG. In the Brain100 studio program, if you complete a spatial navigation measurement using VR goggles and a health check on disease risk factors established by the WHO, we will provide you with a brain health report that includes preventive advice.
A company that promotes health management, where many of its current employees believe that dementia is the last disease they want to develop, and a health checkup center that plays an important role in preventing Alzheimer’s disease from an extremely early stage and providing reliable screening. We are expanding the service to large companies that own shopping malls and multiple stores, where brain health checks can be more easily and easily performed. With the approval of Alzheimer’s disease treatment drugs and the start of their introduction into clinical practice, we believe that the role of ultra-early screening using MIG VR measurement will become
■[Company Profile] ~ Zero Alzheimer’s disease cases in 20 years ~ Company name: MIG Co., Ltd.
Representative Director: Hidetaka Kai
Capital: 142,050,550 yen (as of August 1, 2023)
Founded: September 1, 2017
Business details: Brain100 studio business (https://brain100studio.com/) Directly managed studio: Hidekazu Sakuragaoka Residence No. 516, 29-24 Sakuragaoka-cho, Shibuya-ku■ [MIG Representative Director and CEO Profile]
Hidetaka Kai lost his mother to dementia after 10 years of nursing care. During the last four years of his life, he couldn’t even recognize his mother, and he couldn’t forget the sad expression on his face as he looked at her, so he decided to start MIG that same year. He has held executive positions at Arthur D. Little, an American management consulting firm, Sun Microsystems, Fuji Xerox, Dimension Data Japan & APAC, and AXA Life Insurance. Graduated from Waseda University’s School of Science and Engineering, was a visiting researcher at Massachusetts Institute of Technology’s Institute of Advanced Technology, and holds a master’s degree in business administration from the same university’s Sloan School of Management. ■[MIG Director CSO Profile]
Akihiko Takashima (Professor, Department of Life Sciences, Faculty of Science, Gakushuin University). He assumed his current position after serving as a researcher at the U.S. FDA, senior researcher at Mitsubishi Kasei Life Science Institute, director of the RIKEN Alzheimer’s Disease Laboratory, and director of longevity neurobiology at the National Center for Geriatrics and Gerontology. Master of Science, Department of Biology, Faculty of Science, Kyushu University, Ph.D. in Neurobiology.His recent publications include “Learning with JIN: Super-Early Detection and Prevention Methods for Dementia” (Shueisha), “Your Brain Gets Stronger and Stronger!” Amazing Ways to Walk Around the Earth” (Gakken), etc.
Your brain will become stronger and stronger – amazing ways to walk around the world
-Contact information for media inquiries regarding this matter- MIG Co., Ltd. Contact person: Tatsuro Odawara Hidekazu Sakuragaoka Residence No. 516, 29-24 Sakuragaoka-cho, Shibuya-ku, Tokyo Phone: 03-4500-8261 Mail: email@example.com Thank you very much for reading.
More details about this release: